// App-Quantinova.ai

DXT53 : Efficacy of Cladribine Tablets 3.5mg/Kg in Patients with Relapsing Multiple Sclerosis Aged Above and below 45 Years; Clarity and Clarity Extension

Researchers

Presenter

  • Gavin Giovannoni

Principal Investigators

  • Kottil Rammohan

  • Stuart Cook

  • Per Soelberg-Sorensen

  • Patrick Vermersch

  • Fernando Dangond

  • Birgit Keller

  • Elisabetta Verdun di Cantogno

Medical Centers

  • Rutgers, The State University of New Jersey, New Jersey Medical School

  • Université de Lille, CHU Lille, LIRIC-INSERM U995, FHU Imminent Lille France

  • University of Milan

  • Queen Mary University of London and Blizard Institute Barts and The London School of Medicine and Dentistry London United Kingdom

Locations

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00213135

  • NCT00641537

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved